Literature DB >> 2867773

Circulating autologous stem cells collected in very early remission from acute non-lymphoblastic leukaemia produce prompt but incomplete haemopoietic reconstitution after high dose melphalan or supralethal chemoradiotherapy.

C A Juttner, L B To, D N Haylock, A Branford, R J Kimber.   

Abstract

Haemopoietic reconstitution (HR) using autologous peripheral blood stem cells (PBSC) was attempted after intensive chemotherapy or chemoradiotherapy in two patients with relapsed acute non-lymphoblastic leukaemia (ANLL). The PBSC were collected by leukapheresis very early in first remission and cryopreserved in liquid nitrogen. Both patients demonstrated early evidence of trilineage engraftment. The first patient received melphalan 200 mg/m2 followed by rescue with 1.3 X 10(8) mononuclear cells/kg body weight containing 29 X 10(4) granulocyte-macrophage progenitor cells (CFU-GM)/kg, and HR was evident by Day 14. The second patient was treated with supralethal chemoradiotherapy followed by rescue with 3.0 X 10(8) mononuclear cells/kg containing 23 X 10(4) CFU-GM/kg. He demonstrated early engraftment with near normal peripheral blood counts by Day 16. There was a subsequent fall in both bone marrow cellularity and peripheral blood counts to a level of low but persistent activity. There was a further phase of haematological recovery from 8 weeks following transplantation with an increase in peripheral blood counts and bone marrow cellularity until final relapse at 13 weeks. This study demonstrates that circulating stem cells have haemopoietic reconstitutive capacity, previously only shown with buffy coat cells from chronic granulocytic leukaemia. The minimum number of PBSC required for satisfactory engraftment remains unknown, although it seems probable that the ratio of pluripotent stem cells to committed progenitor cells is lower in very early remission peripheral blood than in either allogeneic normal bone marrow or autologous bone marrow collected later in stable remission. The question of leukaemic contamination of the PBSC remains to be answered.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2867773     DOI: 10.1111/j.1365-2141.1985.tb02888.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  12 in total

Review 1.  ACP Broadsheet No 134: December 1992. How to harvest bone marrow for transplantation.

Authors:  R Jones; A K Burnett
Journal:  J Clin Pathol       Date:  1992-12       Impact factor: 3.411

Review 2.  The long road to the thymus: the generation, mobilization, and circulation of T-cell progenitors in mouse and man.

Authors:  Daniel A Zlotoff; Benjamin A Schwarz; Avinash Bhandoola
Journal:  Semin Immunopathol       Date:  2008-10-17       Impact factor: 9.623

Review 3.  A (selective) history of Australian involvement in cytokine biology.

Authors:  Nicos A Nicola
Journal:  Cytokine Growth Factor Rev       Date:  2013-03-30       Impact factor: 7.638

Review 4.  Current clinical indications for plerixafor.

Authors:  Stefan Fruehauf
Journal:  Transfus Med Hemother       Date:  2013-07-19       Impact factor: 3.747

5.  Granulocyte colony-stimulating factor produces long-term changes in gene and microRNA expression profiles in CD34+ cells from healthy donors.

Authors:  Alicia Báez; Beatriz Martín-Antonio; José I Piruat; Concepción Prats; Isabel Álvarez-Laderas; M Victoria Barbado; Magdalena Carmona; Álvaro Urbano-Ispizua; Jose Antonio Pérez-Simón
Journal:  Haematologica       Date:  2013-09-20       Impact factor: 9.941

6.  Autografting with blood progenitor cells: predictive value of preapheresis blood cell counts on progenitor cell harvest and correlation of the reinfused cell dose with hematopoietic reconstitution.

Authors:  N Schwella; W Siegert; J Beyer; O Rick; J Zingsem; R Eckstein; S Serke; D Huhn
Journal:  Ann Hematol       Date:  1995-11       Impact factor: 3.673

Review 7.  Prospects for cure in leukaemia.

Authors:  J M Goldman
Journal:  J Clin Pathol       Date:  1987-09       Impact factor: 3.411

8.  Cyclophosphamide/granulocyte colony-stimulating factor induces hematopoietic stem cells to proliferate prior to mobilization.

Authors:  S J Morrison; D E Wright; I L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

9.  Spanish Society of Medical Oncology consensus for the use of haematopoietic colony-stimulating factors in cancer patients.

Authors:  Alfredo Carrato; Luis Paz-Ares Rodríguez; Alvaro Rodríguez Lescure; Ana M Casas Fernández de Tejerina; Eduardo Díaz Rubio García; Pedro Pérez Segura; Manuel Constenla Figueiras; Rocío García Carbonero; José Gómez Codina; Ana Lluch Hernández; José Pablo Maroto Rey; Miguel Martín Jiménez; José Ignacio Mayordomo Cámara; José Andrés Moreno Nogueira; Antonio Rueda Domínguez
Journal:  Clin Transl Oncol       Date:  2009-07       Impact factor: 3.405

10.  Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium.

Authors:  J L Gabrilove; A Jakubowski; K Fain; J Grous; H Scher; C Sternberg; A Yagoda; B Clarkson; M A Bonilla; H F Oettgen
Journal:  J Clin Invest       Date:  1988-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.